论文信息 - Combined Targeted Therapies for First‐line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab‐Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib - 字舞流文

Combined Targeted Therapies for First‐line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab‐Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

H. Linden | B. Kurland | J. Gralow | L. Korde | V. Gadi | J. Specht | M. Redman | E. Rodler | K. Baker | Isaac C. Jenkins | M. Garrison | Lynn Symonds | Carol van Haelst | Q. Wu | Julie C. Smith | Jeanne Anderson